Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $95,108.48 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,384 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48. Following the completion of the transaction, the insider now owns 100,165 shares in the company, valued at $6,883,338.80. This represents a 1.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Stock Performance

Shares of Insmed stock opened at $72.51 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $12.97 billion, a P/E ratio of -13.06 and a beta of 1.12. The business has a fifty day simple moving average of $71.18 and a two-hundred day simple moving average of $72.57. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same period in the previous year, the firm earned ($1.10) EPS. Insmed’s quarterly revenue was up 18.1% on a year-over-year basis. On average, equities analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new position in shares of Insmed during the third quarter valued at $30,000. GAMMA Investing LLC increased its holdings in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 627 shares in the last quarter. JCIC Asset Management Inc. bought a new position in shares of Insmed during the third quarter valued at $133,000. Finally, Quantbot Technologies LP bought a new position in shares of Insmed during the third quarter valued at $133,000.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Bank of America raised their price target on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. JPMorgan Chase & Co. raised their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.